You are here

The Journal of clinical investigation DOI:10.1172/JCI66343

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

Publication TypeJournal Article
Year of Publication2013
AuthorsSerra, V, Eichhorn, PJ, García-García, C, Ibrahim, YH, Prudkin, L, Sánchez, G, Rodríguez, O, Antón, P, Parra, JL, Marlow, S, Hahn, WC, Kim, SY, Baselga, J
JournalThe Journal of clinical investigation
Date Published2013/06/03

The PI3K signaling pathway regulates diverse cellular processes, including proliferation, survival, and metabolism, and is aberrantly activated in human cancer. As such, numerous compounds targeting the PI3K pathway are currently being clinically evaluated for the treatment of cancer, and several have shown some early indications of efficacy in breast cancer. However, resistance against these agents, both de novo and acquired, may ultimately limit the efficacy of these compounds. Here, we have taken a systematic functional approach to uncovering potential mechanisms of resistance to PI3K inhibitors and have identified several genes whose expression promotes survival under conditions of PI3K/mammalian target of rapamycin (PI3K/mTOR) blockade, including the ribosomal S6 kinases RPS6KA2 (RSK3) and RPS6KA6 (RSK4). We demonstrate that overexpression of RSK3 or RSK4 supports proliferation upon PI3K inhibition both in vitro and in vivo, in part through the attenuation of the apoptotic response and upregulation of protein translation. Notably, the addition of MEK- or RSK-specific inhibitors can overcome these resistance phenotypes, both in breast cancer cell lines and patient-derived xenograft models with elevated levels of RSK activity. These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.